Cheang, M. et al., Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET
Denkert, C., et al., Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib
Bustos M., et al., Cell-free plasma microRNAs that identify patients with glioblastoma
Stratakis, N., et al., Associations between liver PFAS concentrations and plasma extracellular miRNAs in a cohort of adolescents undergoing bariatric surgery, Environemental Health Perspectives, https://ehp.niehs.nih.gov/doi/abs/10.1289/isee.2021.O-TO-140
Kwak, M., et al., Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates, J Transl Med 19, 371 (2021). https://doi.org/10.1186/s12967-021-03044-5
Maurits, M., et al. The Relationship of Genetics and Clinically suspect Arthralgia in RA Development assessed using HC, CSA and RA Patients. Annals of Rheumatic Diseases 2021(80):1
Strebkova, E., et al. Evaluation of the Effect of mTOR Expression on the Clinical Manifestations of Knee Osteoarthritis in Obese and Normal Weight Patients. Annals of Rheumatic Diseases 2021(80):1
Dorner, T., et al. Antigen-experienced CXCR5- CD19low B cells are plasmablast precursors expanded in SLE. medRxiv preprint May 27, 2021 https://doi.org/10.1101/2021.05.25.21257784doi
Bustos, M. A., et al. Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma. J Clin Oncol 39, 2021 (suppl 15; abstr e16577); DOI: 10.1200/JCO.2021.39.15_suppl.e16577
Denkert, C., et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. J Clin Oncol 39, 2021 (suppl 15; abstr 519) DOI: 10.1200/JCO.2021.39.15_suppl.519
Loibl, S., et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 39, 2021 (suppl 15; abstr 506) DOI: 10.1200/JCO.2021.39.15_suppl.506
Marmé, F., et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol 39, 2021 (suppl 15; abstr 518). DOI 10.1200/JCO.2021.39.15_suppl.518
Page last updated April 19, 2022